Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/109149
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Bezu, Lucillia | - |
dc.contributor.author | Silva, Lígia C. Gomes da | - |
dc.contributor.author | Dewitte, Heleen | - |
dc.contributor.author | Breckpot, Karine | - |
dc.contributor.author | Fucikova, Jitka | - |
dc.contributor.author | Spisek, Radek | - |
dc.contributor.author | Galluzzi, Lorenzo | - |
dc.contributor.author | Kepp, Oliver | - |
dc.contributor.author | Kroemer, Guido | - |
dc.date.accessioned | 2023-09-29T08:14:38Z | - |
dc.date.available | 2023-09-29T08:14:38Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1664-3224 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/109149 | - |
dc.description.abstract | The term "immunogenic cell death" (ICD) is commonly employed to indicate a peculiar instance of regulated cell death (RCD) that engages the adaptive arm of the immune system. The inoculation of cancer cells undergoing ICD into immunocompetent animals elicits a specific immune response associated with the establishment of immunological memory. Only a few agents are intrinsically endowed with the ability to trigger ICD. These include a few chemotherapeutics that are routinely employed in the clinic, like doxorubicin, mitoxantrone, oxaliplatin, and cyclophosphamide, as well as some agents that have not yet been approved for use in humans. Accumulating clinical data indicate that the activation of adaptive immune responses against dying cancer cells is associated with improved disease outcome in patients affected by various neoplasms. Thus, novel therapeutic regimens that trigger ICD are urgently awaited. Here, we discuss current combinatorial approaches to convert otherwise non-immunogenic instances of RCD into bona fide ICD. | pt |
dc.description.sponsorship | GK issupportedbytheLiguecontreleCancer(équipelabelisée); AgenceNationaldelaRecherche(ANR);Associationpour larecherchesurlecancer(ARC);CancéropôleIle-de-France; InstitutNationalduCancer(INCa);FondationBettencourt- Schueller;FondationdeFrance;FondationpourlaRecherche Médicale(FRM);theEuropeanCommission(ArtForce);the EuropeanResearchCouncil(ERC);theLabExImmuno- Oncology;theSIRICStratifiedOncologyCellDNARepair andTumorImmuneElimination(SOCRATE);theSIRIC CancerResearchandPersonalizedMedicine(CARPEM); andtheParisAllianceofCancerResearchInstitutes (PACRI). | pt |
dc.language.iso | eng | pt |
dc.publisher | Frontiers Media S.A. | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | ATP | pt |
dc.subject | autophagy | pt |
dc.subject | calreticulin | pt |
dc.subject | endoplasmic reticulum stress | pt |
dc.subject | HMGB1 | pt |
dc.subject | type I interferon | pt |
dc.title | Combinatorial strategies for the induction of immunogenic cell death | pt |
dc.type | article | - |
degois.publication.firstPage | 187 | pt |
degois.publication.issue | APR | pt |
degois.publication.title | Frontiers in Immunology | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.3389/fimmu.2015.00187 | pt |
degois.publication.volume | 6 | pt |
dc.date.embargo | 2015-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | open | - |
item.openairetype | article | - |
item.languageiso639-1 | en | - |
item.fulltext | Com Texto completo | - |
item.cerifentitytype | Publications | - |
crisitem.author.researchunit | CQC - Coimbra Chemistry Centre | - |
crisitem.author.parentresearchunit | Faculty of Sciences and Technology | - |
crisitem.author.orcid | 0000-0003-0624-8819 | - |
Aparece nas coleções: | FCTUC Química - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Combinatorial strategies for the induction of immunogenic cell death.pdf | 3.24 MB | Adobe PDF | Ver/Abrir |
Visualizações de página
66
Visto em 28/ago/2024
Downloads
57
Visto em 28/ago/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons